“…To date, many studies have explored the association of functional polymorphisms of CAV1 with the susceptibility to oral (Bau et al, 2011), breast (Liu et al, 2011), colorectal (Yang et al, 2010), gastric (Zhang et al, 2014) and hepatocellular (Hsu et al, 2013) cancers. For ESCC, several previous studies have reported clinical impact of CAV1 expression in esophageal carcinoma by immunohistochemical or cDNA expression array analysis, indicating a statistically significant increased expression of CAV1 mRNA and protein levels (Hu et al, 2001;Kato et al, 2002).…”